What Bicara Therapeutics Inc. does.

We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap.

By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the TME. Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will drive the tumor penetration of immune cells that lead to deep and durable responses and an increase in overall survival, or OS.

Revenue and profit, by fiscal year.

More on BCAX.

• Bicara Therapeutics Inc. summary
• Bicara Therapeutics Inc. financial statements
• Bicara Therapeutics Inc. key metrics
• Bicara Therapeutics Inc. health scores and style box
• Bicara Therapeutics Inc. earnings
• Bicara Therapeutics Inc. dividends
• Bicara Therapeutics Inc. valuation
• Bicara Therapeutics Inc. ownership and insiders
• Bicara Therapeutics Inc. peers

Figures from Bicara Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.